MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Vaxart Inc

Open

0.38 8.57

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.35

Max

0.37

Belangrijke statistieken

By Trading Economics

Inkomsten

2.1M

-12M

Verkoop

10M

15M

EPS

-0.05

Winstmarge

-78.927

Werknemers

105

EBITDA

3.7M

-8.6M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+733.33% upside

Dividenden

By Dow Jones

Volgende Winsten

12 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-58M

73M

Vorige openingsprijs

-8.19

Vorige sluitingsprijs

0.38

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Vaxart Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr 2025, 23:51 UTC

Marktinformatie

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr 2025, 23:37 UTC

Top Nieuws

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr 2025, 23:36 UTC

Top Nieuws

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr 2025, 23:13 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr 2025, 23:09 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 22:48 UTC

Top Nieuws

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr 2025, 22:47 UTC

Marktinformatie

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr 2025, 22:38 UTC

Marktinformatie
Winsten

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr 2025, 22:24 UTC

Marktinformatie
Winsten

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr 2025, 22:23 UTC

Winsten

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr 2025, 22:09 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr 2025, 22:00 UTC

Marktinformatie
Winsten

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr 2025, 21:39 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr 2025, 21:23 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr 2025, 21:04 UTC

Winsten

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr 2025, 21:02 UTC

Winsten

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Vergelijking

Prijswijziging

Vaxart Inc Prognose

Koersdoel

By TipRanks

733.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3 USD  733.33%

Hoogste 4 USD

Laagste 2 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vaxart Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.3439 / 0.37Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.